The hUC-MSC-treated group exhibited significant downregulation of MCP-1 and KC, while showing a decreasing trend (though not statistically significant) in IL-6, IL-1β, CCL13, and TNF levels (Fig. 6E, F ).
← all excerpts
Th17-driven CD8<sup>+</sup> T cells in hUC-MSC and CAR T-cell dual immunotherapy for superior anti-tumor efficacy.
1
—
—